Romidepsin Maintenance After Allogeneic Stem Cell Transplantation

Inclusion Criteria: * Age 18 to 70 years of age. * Diagnosis of either Cutaneous T-Cell Lymphoma; T-Prolymphocytic Leukemia; T-Large Granulocytic Leukemia; T-Lymphoblastic Leukemia/lymphoma; or Peripheral T-Cell Lymphoma, Natural Killer/T-cell lymphoma for whom allogeneic stem cell transplantation is indicated. * An 10/10 or 8/8 HLA matched (high resolution typing at A, B, C, DRB1, DQ1) sibling or unrelated donor. * EF\>/= 50% on MUGA scan or Echocardiogram. * FEV1, FVC and corrected DLCO \>/= 40%. * Adequate renal function, as defined by estimated serum creatinine clearance \>/=50 ml/min (using the Cockcroft-Gault formula: creatinine clearance = \[(140-age)\*kg/(72\*serum creatinine)\] \* 0.85 if female) and/or serum creatinine \</=1.6 mg/dL. Renal function will be calculated using ideal body weight (IBW), unless a patient weights \>40% of their IBW, then adjusted body weight will be utilized. * Serum bilirubin \</= 1.5 x upper limit of normal. * SGOT and SGPT \</= 2 x upper limit of normal. * Able to sign informed consent. * Men and women of reproductive potential must agree to follow accepted birth control methods for the duration of the study. Female subject is either post-menopausal or surgically sterilized or willing to use an acceptable method of birth control (i.e., a hormonal contraceptive, intra-uterine device, diaphragm with spermicide, condom with spermicide, or abstinence) for the duration of the study. Male subject agrees to use an acceptable method for contrac…